1. Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin
   Poupak Fallahi et al, 2022, Seminars in Cancer Biology CrossRef
2. Poorly Differentiated and Anaplastic Thyroid Cancer: Insights into Genomics, Microenvironment and New Drugs
   Alessandro Prete et al, 2021, Cancers CrossRef
3. VEGA is an interpretable generative model for inferring biological network activity in single-cell transcriptomics
   Lucas Seninge et al, 2021, Nature Communications CrossRef
4. Mutations in the RAS pathway as potential precision medicine targets in treatment of rhabdomyosarcoma
   Norio Nakagawa et al, 2019, Biochemical and Biophysical Research Communications CrossRef
5. Substantial intrinsic variability in chemoradiosensitivity of newly established anaplastic thyroid cancer cell-lines
   Sigurdur Gretarsson et al, 2020, Acta Oto-Laryngologica CrossRef
6. A Role for Maternal Factors in Suppressing Cytoplasmic Incompatibility
   AJM Zehadee Momtaz et al, 2020, Frontiers in Microbiology CrossRef
7. CERN Large Hadron Collider (LHC) Radiation Source for Magnetic Resonance Biospectroscopy in Metabolic and Molecular Imaging and Diagnosis of Cancer
   Alireza Heidari et al, 2022, Journal of New Developments in Chemistry CrossRef
8. Recent advances in the management of anaplastic thyroid cancer
   Simone De Leo et al, 2020, Thyroid Research CrossRef
9. Evaluating new treatments for anaplastic thyroid cancer
   Andrés Coca-Pelaz et al, 2022, Expert Review of Anticancer Therapy CrossRef
10. Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status
    Sae Ishihara et al, 2019, International Journal of Oncology CrossRef
11. Design and biological evaluation of novel triaryl pyrazoline derivatives with dioxane moiety for selective BRAFV600E inhibition
    Hong-Lin Li et al, 2018, European Journal of Medicinal Chemistry CrossRef
12. Combination BRAFV600E Inhibition with the Multitargeting Tyrosine Kinase Inhibitor Axitinib Shows Additive Anticancer Activity in BRAFV600E-Mutant Anaplastic Thyroid Cancer
    Viswanath Gunda et al, 2023, Thyroid® CrossRef
13. Epigenetic Targets and Their Inhibitors in Thyroid Cancer Treatment
    Ke Zhang et al, 2023, Pharmaceuticals CrossRef
14. Radiotherapy combined with immunotherapy successfully treated one case of anaplastic thyroid cancer: A case report
    Yurou Xing et al, 2023, Frontiers in Oncology CrossRef
15. Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice
    Rong Wang et al, 2019, Molecular Cancer Therapeutics CrossRef
16. The potential role of reprogrammed glucose metabolism: an emerging actionable codependent target in thyroid cancer
    Sai-li Duan et al, 2023, Journal of Translational Medicine CrossRef
17. Anaplastic Thyroid Carcinoma: Current Issues in Genomics and Therapeutics
    Ichiro Abe et al, 2021, Current Oncology Reports CrossRef
18. Inhibition of IRAK1/4 enhances the antitumor effect of lenvatinib in anaplastic thyroid cancer cells
    Yoshifumi Kawamura et al, 2021, Cancer Science CrossRef
19. Recent advances in precision medicine for the treatment of anaplastic thyroid cancer
    Silvia Martina Ferrari et al, 2019, Expert Review of Precision Medicine and Drug Development CrossRef
20. Novel treatment options for anaplastic thyroid cancer
    Poupak Fallahi et al, 2017, Expert Review of Endocrinology & Metabolism CrossRef
21. Combinatorial Therapies in Thyroid Cancer: An Overview of Preclinical and Clinical Progresses
    Gheysen Laetitia et al, 2020, Cells CrossRef